Genelabs Technologies, Inc.

Kenneth E Schwartz

Marc J Gurwith

Jagdish Parasrampuria

Maxine B Yonker

A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e.g., for treatment of systemic lupus erythematosus (SLE).

Treatment of subnormal bone mineral density

Disclosed are improved pharmaceutical formulations comprising dehydroepiandrosterone (DHEA), enriched in selected polymorphic forms, for therapeutic applications. In one embodiment, the formulation comprises, in solid form, DHEA, at least 85% of which is present as a single polymorph selected from the form I polymorph or the form II polymorph, and at least one pharmaceutical excipient. Methods for making and using such compositions are also disclosed.

DHEA composition and method

This invention provides a method of treating systemic lupus erythematosus (SLE) with (DHEA) and a related pharmaceutical product.

Growing community of inventors

San Mateo, CA, United States of America

Kenneth E Schwartz